Change the time of intake of aspirin for the reduction of cardiovascular disease.
Phase 1
- Conditions
- The medical condioton to be investigated is recurrent cardiovascular diseaseTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- EUCTR2018-001328-21-NL
- Lead Sponsor
- eiden University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 4000
Inclusion Criteria
patients who already use low-dose aspirin for secondary prevention of cardiovascular events and use a multidose drug dispensing
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1000
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 3000
Exclusion Criteria
Insufficient knowledge of the Dutch language
Patients currently participating in another (clinical) trial or study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does EUCTR2018-001328-21-NL investigate in chronotherapy with aspirin for cardiovascular disease?
How does chronotherapy with aspirin in EUCTR2018-001328-21-NL compare to standard dosing for recurrent cardiovascular disease prevention?
Which circadian rhythm biomarkers are associated with aspirin chronotherapy efficacy in Eiden University Medical Center's CVD trial?
What adverse events are reported in EUCTR2018-001328-21-NL's Phase I aspirin chronotherapy trial for cardiovascular disease?
Are there combination therapies with aspirin chronotherapy that improve cardiovascular disease outcomes compared to monotherapy?